The first gene-editing therapies for HIV/Aids are entering trials but the virus is proving once again that it is a master at ...
SHELTON, CONNECTICUT / ACCESS Newswire / November 10, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the “Company”) today ...
Merck said on Wednesday its experimental oral HIV medicine was found to be non-inferior to Gilead Sciences' top-selling drug ...
Gilead’s investigational drug combo bic/len could help lower the pill burden in patients with virologically suppressed HIV ...
Organizations that provide services like HIV education and living recommendations are being forced to cut programming after ...
Opportunistic infections target people with weakened immune systems, including those with HIV. These conditions can lead to ...
To mark World AIDS Day, the Institute for Contemporary Arts will screen our film tackling the collapse of USAID funding ...
The candlelighting ceremony at the World AIDS Day commemorative event. (Photo: PIA Samar) An early World AIDS Day observance ...
Merck said on Wednesday that its experimental oral HIV treatment met the main goal of a late-stage trial. The company said ...
Merck & Co. has reported another phase 3 win for islatravir in HIV, advancing its efforts to establish the near-approval ...
Gilead Sciences, Inc. is rated a Buy with robust profitability, solid dividend, prudent M&A and 15-20% upside potential. Read ...
Stocktwits on MSN
Merck Says Its Two-Drug Regimen For HIV Treatment Proven Non-Inferior To Gilead’s Biktarvy In Study
The safety profile of the regimen was also found to be comparable to Biktarvy. ・Merck now intends to present findings from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback